Company Profile

Abgenix Inc
Profile last edited on: 3/14/18      CAGE:       UEI:

Business Identifier: Biopharmaceutical company: human therapeutic antibodies
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6701 Kaiser Drive
Fremont, CA 94555
   (510) 608-6500
Location: Single
Congr. District: 15
County: Alameda

Public Profile

In December 2005 Abgenix Inc was acquired by Amgen itself - albeit on small scale - an SBIR involved firm in its early days. Formed by Cell Genesys Inc. (Foster City, California) Abgenix was established to develop the company's human monoclonal antibodies for pharmaceutical products. Abgenix platform includes leading technologies and state-of-the-art manufacturing capabilities that enable the rapid generation, selection, and production of high affinity, fully human antibodies for a variety of disease targets. Management are leveraging our leadership position in human antibody technology to build a diversified product portfolio. Our fully integrated product development capabilities range from the generation/characterization of antibodies to full-scale production in our state-of-the-art manufacturing facility. Core to our discovery platform are XenoMouse® and XenoMaxTM—proprietary technologies used to generate large pools of fully human antibodies from which to choose appropriate candidates. Once candidates are selected, they can be advanced through clinical development and commercial-scale production via proprietary cell lines and versatile process development technologies, as we leverage our process sciences plant and flexible clinical- and commercial-scale manufacturing infrastructure to streamline scale-up and minimize risks associated with biologics manufacturin

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 1 NIH $88,100
Project Title: An Expression System For Antibody Manufacturing
2000 1 NIH $92,714
Project Title: Modified Antibodies With Increased Serum Half-Life

Key People / Management

  William R Ringo -- President

  Michael L Gallo

Company News

There are no news available.